Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells

被引：4

作者：

Sakai, Osamu ^{[1
]}

Ogino, Shoji ^{[2
]}

Tsukui, Toshihiro ^{[2
]}

Igase, Masaya ^{[1
]}

Mizuno, Takuya ^{[1
]}

机构：

[1] Yamaguchi Univ, Joint Grad Sch Vet Med, Lab Mol Diagnost & Therapeut, 1677-1 Yoshida, Yamaguchi 7538515, Japan

[2] Nippon Zenyaku Kogyo Co Ltd, Koriyama, Fukushima 9630196, Japan

来源：

JOURNAL OF VETERINARY MEDICAL SCIENCE | 2021年 / 83卷 / 10期

关键词：

adoptive immunotherapy; canine; CD20; chimeric antigen receptorT cell; monoclonal antibody; RITUXIMAB; LYMPHOMA; THERAPY; MODEL; DOGS;

D O I：

10.1292/jvms.21-0326

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

Chimeric antigen receptor (CAR) CAR-T cell therapy targeting CD20 can be a novel adoptive cell therapy for canine patients with B-cell malignancy. After injection of the CAR-T cells in vivo, monitoring circulating CAR-T cells is essential to prove in vivo persistence of CAR-T cells. In this study, we developed a novel monoclonal antibody against canine CD20 CAR, whose single-chain variable fragment was derived from the our previously reported anti-canine CD20 therapeutic antibody. Furthermore, we proved that this monoclonal antibody can detect therapeutic anti-canine CD20 chimeric antibody in the serum from healthy beagle dogs injected with the therapeutic antibody for safety study. This monoclonal antibody is a useful tool for monitoring both canine CD20-CAR-T cells and anti-canine CD20 therapeutic antibody for canine lymphoma.

引用

页码：1495 / 1499

页数：5

共 50 条

[31] Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma [J].

Wen, Hairuo ;

Lou, Xiaoyan ;

Qu, Zhe ;

Qin, Chao ;

Jiang, Hua ;

Yang, Ying ;

Kang, Liqing ;

Geng, Xingchao ;

Yu, Lei ;

Huang, Ying .

DISCOVER ONCOLOGY, 2022, 13 (01)

[32] Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies [J].

Png, Yi Tian ;

Vinanica, Natasha ;

Kamiya, Takahiro ;

Shimasaki, Noriko ;

Coustan-Smith, Elaine ;

Campana, Dario .

BLOOD ADVANCES, 2017, 1 (25) :2348-2360

[33] A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells [J].

Piccione, Emily C. ;

Juarez, Silvia ;

Liu, Jie ;

Tseng, Serena ;

Ryan, Christine E. ;

Narayanan, Cyndhavi ;

Wang, Lijuan ;

Weiskopf, Kipp ;

Majeti, Ravindra .

MABS, 2015, 7 (05) :946-956

[34] Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials [J].

Xu, Xiao-Jun ;

Zhao, Hai-Zhao ;

Tang, Yong-Min .

LEUKEMIA & LYMPHOMA, 2013, 54 (02) :255-260

[35] Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia [J].

Maciocia, Nicola ;

Hoekx, Malika ;

Acuna, Ciaran ;

Wade, Brandon ;

Burley, Amy ;

Ramanayake, Saumya ;

Nannini, Francesco ;

Wawrzyniecka, Patrycja A. ;

Karpanasamy, Thaneswari ;

Schuldt, Maria ;

Ng, Stephanie ;

Ferrari, Mathieu ;

Marafioti, Teresa ;

Gritti, Giuseppe ;

Onuoha, Shimobi ;

O'Connor, David ;

Lee, Lydia ;

Mansour, Marc ;

Khwaja, Asim ;

Pule, Martin ;

Maciocia, Paul .

SCIENCE TRANSLATIONAL MEDICINE, 2025, 17 (794)

[36] CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer [J].

Li, Ming ;

Li, Shanglin ;

Zhao, Ruocong ;

Lv, Jiang ;

Zheng, Diwei ;

Qin, Le ;

Li, Siyu ;

Wu, Qiting ;

Long, Youguo ;

Tang, Zhaoyang ;

Tang, Yan-Lai ;

Yang, Lihua ;

Yao, Yao ;

Luo, Xuequn ;

Li, Peng .

CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) :2409-2419

[37] CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia [J].

Lorentzen, C. L. ;

Straten, P. T. .

SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2015, 82 (04) :307-319

[38] High CD62L expression predicts the generation of chimeric antigen receptor T cells with potent effector functions [J].

Kasuya, Hitomi ;

Zhang, Haosong ;

Ito, Yusuke ;

Yoshikawa, Toshiaki ;

Nakashima, Takahiro ;

Li, Yang ;

Matsukawa, Tetsuya ;

Inoue, Satoshi ;

Kagoya, Yuki .

INTERNATIONAL IMMUNOLOGY, 2024, 36 (07) :353-364

[39] Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells [J].

D'Arena, Giovanni ;

Ruggieri, Vitalba ;

D'Auria, Fiorella ;

La Rocca, Francesco ;

Simeon, Vittorio ;

Statuto, Teodora ;

Caivano, Antonella ;

Telesca, Donatella ;

Del Vecchio, Luigi ;

Musto, Pellegrino .

LEUKEMIA & LYMPHOMA, 2015, 56 (08) :2458-2459

[40] Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL [J].

Rossi, John ;

Paczkowski, Patrick ;

Shen, Yueh-Wei ;

Morse, Kevin ;

Flynn, Brianna ;

Kaiser, Alaina ;

Ng, Colin ;

Gallatin, Kyle ;

Cain, Tom ;

Fan, Rong ;

Mackay, Sean ;

Heath, James R. ;

Rosenberg, Steven A. ;

Kochenderfer, James N. ;

Zhou, Jing ;

Bot, Adrian .

BLOOD, 2018, 132 (08) :804-814

← 1 2 3 4 5 →